IMS Capital Management Has $1.47 Million Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

IMS Capital Management grew its stake in Merck & Co., Inc. (NYSE:MRKGet Rating) by 20.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 16,147 shares of the company’s stock after purchasing an additional 2,704 shares during the quarter. Merck & Co., Inc. comprises approximately 1.0% of IMS Capital Management’s holdings, making the stock its 25th largest holding. IMS Capital Management’s holdings in Merck & Co., Inc. were worth $1,472,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in MRK. Bromfield Sneider Wealth Advisors acquired a new position in Merck & Co., Inc. in the first quarter valued at about $79,000. Hikari Power Ltd grew its position in shares of Merck & Co., Inc. by 5.0% in the 1st quarter. Hikari Power Ltd now owns 23,630 shares of the company’s stock valued at $1,939,000 after purchasing an additional 1,130 shares during the period. Financial Management Professionals Inc. increased its stake in Merck & Co., Inc. by 9.3% during the 2nd quarter. Financial Management Professionals Inc. now owns 3,414 shares of the company’s stock worth $311,000 after purchasing an additional 291 shares in the last quarter. ACG Wealth raised its holdings in Merck & Co., Inc. by 5.6% during the 1st quarter. ACG Wealth now owns 13,523 shares of the company’s stock worth $1,110,000 after buying an additional 722 shares during the period. Finally, Mascoma Wealth Management LLC lifted its stake in Merck & Co., Inc. by 36.4% in the first quarter. Mascoma Wealth Management LLC now owns 926 shares of the company’s stock valued at $76,000 after buying an additional 247 shares in the last quarter. 73.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on MRK shares. Atlantic Securities raised their price objective on shares of Merck & Co., Inc. from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, July 13th. Morgan Stanley boosted their price target on Merck & Co., Inc. from $88.00 to $92.00 and gave the company an “equal weight” rating in a report on Friday, July 29th. Mizuho assumed coverage on Merck & Co., Inc. in a report on Friday, June 24th. They set a “buy” rating and a $100.00 price objective for the company. SVB Leerink upped their price target on Merck & Co., Inc. from $105.00 to $109.00 and gave the stock an “outperform” rating in a research report on Monday, September 12th. Finally, Daiwa Capital Markets raised shares of Merck & Co., Inc. from a “neutral” rating to a “buy” rating and raised their price target for the stock from $89.00 to $102.00 in a research note on Wednesday, July 6th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $98.28.

Merck & Co., Inc. Trading Down 1.7 %

Merck & Co., Inc. stock opened at $84.53 on Thursday. The stock has a 50-day simple moving average of $88.96 and a 200 day simple moving average of $87.74. The stock has a market capitalization of $214.14 billion, a P/E ratio of 12.94, a PEG ratio of 1.16 and a beta of 0.33. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.15 and a current ratio of 1.39. Merck & Co., Inc. has a 52 week low of $71.50 and a 52 week high of $95.72.

Merck & Co., Inc. (NYSE:MRKGet Rating) last issued its earnings results on Thursday, July 28th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.67 by $0.20. The company had revenue of $14.59 billion during the quarter, compared to the consensus estimate of $13.85 billion. Merck & Co., Inc. had a return on equity of 48.45% and a net margin of 29.00%. The firm’s revenue for the quarter was up 28.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.31 EPS. Analysts expect that Merck & Co., Inc. will post 7.33 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be issued a dividend of $0.69 per share. This represents a $2.76 annualized dividend and a dividend yield of 3.27%. The ex-dividend date is Wednesday, September 14th. Merck & Co., Inc.’s payout ratio is 42.27%.

About Merck & Co., Inc.

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with's FREE daily email newsletter.